| General Information | |
|---|---|
| ZINC ID | ZINC000071316576 |
| Molecular Weight (Da) | 374 |
| SMILES | O=C(c1cccc2[nH]ccc12)N1CC[C@](O)(c2ccccc2)[C@H]2CCCC[C@H]21 |
| Molecular Formula | C24N2O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 109.194 |
| HBA | 2 |
| HBD | 2 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 28 |
| LogP | 3.329 |
| Activity (Ki) in nM | 0.617 |
| Polar Surface Area (PSA) | 56.33 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.81386536 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 15 |
| Fraction csp3 | 0.38 |
| Ilogp | 2.67 |
| Xlogp3 | 4.02 |
| Wlogp | 3.97 |
| Mlogp | 3.31 |
| Silicos-it log p | 4.11 |
| Consensus log p | 3.62 |
| Esol log s | -4.89 |
| Esol solubility (mg/ml) | 4.79E-03 |
| Esol solubility (mol/l) | 1.28E-05 |
| Esol class | Moderately |
| Ali log s | -4.91 |
| Ali solubility (mg/ml) | 4.65E-03 |
| Ali solubility (mol/l) | 1.24E-05 |
| Ali class | Moderately |
| Silicos-it logsw | -6.48 |
| Silicos-it solubility (mg/ml) | 1.25E-04 |
| Silicos-it solubility (mol/l) | 3.33E-07 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.73 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.46 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.743 |
| Logd | 3.709 |
| Logp | 3.927 |
| F (20%) | 0.944 |
| F (30%) | 0.02 |
| Mdck | 1.52E-05 |
| Ppb | 0.9499 |
| Vdss | 1.016 |
| Fu | 0.0317 |
| Cyp1a2-inh | 0.497 |
| Cyp1a2-sub | 0.583 |
| Cyp2c19-inh | 0.944 |
| Cyp2c19-sub | 0.218 |
| Cl | 3.325 |
| T12 | 0.126 |
| H-ht | 0.934 |
| Dili | 0.563 |
| Roa | 0.215 |
| Fdamdd | 0.514 |
| Skinsen | 0.934 |
| Ec | 0.004 |
| Ei | 0.213 |
| Respiratory | 0.975 |
| Bcf | 0.715 |
| Igc50 | 4.51 |
| Lc50 | 5.069 |
| Lc50dm | 5.343 |
| Nr-ar | 0.24 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.649 |
| Nr-aromatase | 0.912 |
| Nr-er | 0.259 |
| Nr-er-lbd | 0.016 |
| Nr-ppar-gamma | 0.013 |
| Sr-are | 0.382 |
| Sr-atad5 | 0.012 |
| Sr-hse | 0.298 |
| Sr-mmp | 0.81 |
| Sr-p53 | 0.185 |
| Vol | 399.36 |
| Dense | 0.937 |
| Flex | 28 |
| Nstereo | 0.107 |
| Nongenotoxic carcinogenicity | 3 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 0 |
| Qed | 2 |
| Synth | 0.696 |
| Fsp3 | 3.332 |
| Mce-18 | 0.375 |
| Natural product-likeness | 92.182 |
| Alarm nmr | -0.029 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |